menu
    • menu
    [{"orgOrder":0,"company":"Minovia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous CD34+ Cell Enriched with Placenta-Derived Allogeneic Mitochondria","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Minovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Minovia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Minovia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Minovia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"MNV-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Minovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Minovia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Minovia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Minovia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"MNV-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Minovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minovia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Minovia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Minovia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"MNV-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Minovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minovia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Minovia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Minovia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"MNV-201","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Minovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minovia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Minovia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Minovia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MNV-BLD","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Minovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Minovia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Minovia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Minovia Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Minovia Therapeutics","amount2":0.41999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0.41999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Minovia Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Minovia Therapeutics \/ Astellas Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Minovia Therapeutics

    Menu

    Minovia Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Minovia Therapeutics

                            Israel arrow
                            The MedTech Conference
                            Not Confirmed

                            Minovia Therapeutics

                            Israel arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MNV-201

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Minovia Gets FDA Nod for Phase II Trial of MNV-201 in Pearson Syndrome

                            Details : MNV-201, an autologous hematopoietic stem cell product augmented with allogeneic mitochondria. It is being evaluated for the treatment of pearson syndrome.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 03, 2025

                            Lead Product(s) : MNV-201

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Minovia Therapeutics

                            Israel arrow
                            The MedTech Conference
                            Not Confirmed

                            Minovia Therapeutics

                            Israel arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MNV-201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Minovia Gains FDA Clearance for Phase Ib Trial of MNV-201 in Myelodysplastic Syndrome

                            Details : MNV-201, an autologous hematopoietic stem cell product augmented with allogeneic mitochondria. It is being evaluated for the treatment of low risk myelodysplastic syndrome.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 26, 2024

                            Lead Product(s) : MNV-201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Minovia Therapeutics

                            Israel arrow
                            The MedTech Conference
                            Not Confirmed

                            Minovia Therapeutics

                            Israel arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MNV-201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the MNV-201 in Patients with Low Risk MDS

                            Details : MNV-201 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Myelodysplastic Syndromes.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            June 18, 2024

                            Lead Product(s) : MNV-201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Minovia Therapeutics

                            Israel arrow
                            The MedTech Conference
                            Not Confirmed

                            Minovia Therapeutics

                            Israel arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MNV-201

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells En...

                            Details : MNV-201 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Mitochondrial Diseases.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 30, 2023

                            Lead Product(s) : MNV-201

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Minovia Therapeutics

                            Israel arrow
                            The MedTech Conference
                            Not Confirmed

                            Minovia Therapeutics

                            Israel arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MNV-BLD

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Minovia Therapeutics Reports First Clinical Data Demonstrating Disease-Modifying Efficacy and Safety of Mitoch...

                            Details : MNV-BLD is a therapeutic process for enrichment of patient's peripheral hematopoietic stem cells with normal and healthy mitochondria derived from donor blood cells.

                            Product Name : MNV-BLD

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 21, 2022

                            Lead Product(s) : MNV-BLD

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Minovia Therapeutics

                            Israel arrow
                            The MedTech Conference
                            Not Confirmed

                            Minovia Therapeutics

                            Israel arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Undisclosed

                            Sponsor : Astellas Pharma

                            Deal Size : $420.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Progra...

                            Details : The collaboration focuses on allogeneic mitochondrial cell therapies. Astellas will contribute cells from its genetically-engineered, induced pluripotent stem cells. Minovia meanwhile will hand forth its mitochondrial augmentation therapy platform.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $20.0 million

                            July 30, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Undisclosed

                            Sponsor : Astellas Pharma

                            Deal Size : $420.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Minovia Therapeutics

                            Israel arrow
                            The MedTech Conference
                            Not Confirmed

                            Minovia Therapeutics

                            Israel arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous CD34+ Cell Enriched with Placenta-Derived Allogeneic Mitochondria

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With ...

                            Details : MNV-BM-PLC (Autologous CD34+ Cell Enriched with Placenta-Derived Allogeneic Mitochondria) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Mitochondrial Diseases.

                            Product Name : MNV-BM-PLC

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 16, 2020

                            Lead Product(s) : Autologous CD34+ Cell Enriched with Placenta-Derived Allogeneic Mitochondria

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Minovia Therapeutics

                            Israel arrow
                            The MedTech Conference
                            Not Confirmed

                            Minovia Therapeutics

                            Israel arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CD34+ Cell

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-BM-BLD in Pediatric Patients ...

                            Details : CD34+ Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Mitochondrial Diseases.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 27, 2017

                            Lead Product(s) : CD34+ Cell

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth